Janus Henderson Glb Life Scn H1 GBP
Pricing frequency
Daily
Dealing cut off time
17:00
Type
OEIC
Yield
0.04%
NAV
£44.14
Income frequency
Annually
Ongoing charge
0.86%
Latest actual NAV date
16-11-2026
ISIN
IE00BRJ9D748
UCITS
Yes
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 30/09/2026 | % of assets |
|---|---|
| Eli Lilly and Co | 9.61 |
| Johnson & Johnson | 7.78 |
| AbbVie Inc | 4.93 |
| UnitedHealth Group Inc | 4.27 |
| AstraZeneca PLC | 3.71 |
| Thermo Fisher Scientific Inc | 3.35 |
| Novartis AG ADR | 2.73 |
| Roche Holding AG | 2.68 |
| argenx SE ADR | 2.45 |
| Merck & Co Inc | 2.35 |
Investment objective
The Fund’s investment objective is long-term growth of capital. It pursues its objective by investing at least 80% of its net asset value in equities (also known as company shares) located anywhere in the world and selected for their growth potential. The Fund will invest at least 80% of its net asset value in companies that the relevant Sub-Investment Adviser believes have a life sciences orientation. Generally speaking, the “life sciences” relate to maintaining or improving quality of life. Thus, companies with a “life sciences orientation” include companies engaged in research, development, production or distribution of products or services related to health and personal care, medicine or pharmaceuticals. Such companies may also include companies that the relevant Sub-Investment Adviser believes have growth potential mainly as a result of particular products, technology, patents or other market advantages in the life sciences.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.